Login or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Imran H. Yusuf, Barny Foot, James Galloway, Michael R. Ardern-Jones, Sarah-Lucie Watson, Cathy Yelf, Michael A. Burdon, Paul N. Bishop, Andrew J. Lotery. Royal College of Ophthalmologists Guideline Development Group - Hydroxychloroquine and Chloroquine Retinopathy: Recommendations on Screening. https://www.rcophth.ac.uk/standards-publications-research/clinical-guidelines/ Accessed 3 March 2018.
Yusuf IH, Sharma S, Luqmani R, Downes SM. Hydroxychloroquine retinopathy. Eye. 2017;31:828–45.
Alarcon GS, McGwin G, Bertoli AM, et al. Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis. 2007;66:1168–72.
Yates M, Malaiya R, Stack J, Galloway JB. Hydroxychloroquine use: the potential impact of new ocular screening guidelines. Eye. 2018;32:161–2.
Mavrikakis I, Sfikakis PP, Mavrikakis E, et al. The incidence of irreversible retinal toxicity in patients treated with hydroxychloroquine: a reappraisal. Ophthalmology. 2003;110:1321–6.
Richard Smith, Brian Bourke, Stephen Jones, Arul k Rajammal, Alan Silman. Hydroxychloroquine and Ocular Toxicity Recommendations on Screening. The Royal College of Ophthalmologists 2009.
Melles RB, Marmor MF. The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapy. JAMA Ophthalmol. 2014;132:1453–60.
Latasiewicz M, Gourier H, Yusuf IH, et al. Hydroxychloroquine retinopathy: an emerging problem. Eye. 2017;31:972–6.
Imran H. Yusuf, Cathy Yelf. Eye screening for patients taking hydroxychloroquine (Plaquenil®): Macular Society. https://www.macularsociety.org/sites/default/files/resource/Hydroxychloroquine%20-%20access.pdf Accessed 1 March 2018.
Acknowledgements
We thank our expert reviewers, Dr Ron Melles and Mr Alastair Denniston, college members who provided feedback on these draft guidelines and Iris Gordon from the Cochrane Eyes and Vision Group for assistance in searching the evidence basis.
Author contributions
The Multidisciplinary guideline development group was chaired by AJL. IHY was involved in grading the evidence, writing the first draft of the guideline. BF represented The Royal College of Ophthalmologists and supported the guidance development process. PNB, MAB and S-LW provided ophthalmic specialist clinical input. JG represented the British Society for Rheumatology and provided rheumatological specialist clinical input. MRA-J represented the British Association of Dermatologists and provided dermatological specialist clinical input. CY contributed as a Patient and Carer representation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Yusuf, I.H., Foot, B., Galloway, J. et al. The Royal College of Ophthalmologists recommendations on screening for hydroxychloroquine and chloroquine users in the United Kingdom: executive summary. Eye 32, 1168–1173 (2018). https://doi.org/10.1038/s41433-018-0136-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41433-018-0136-x
This article is cited by
-
The incidence, monitoring coverage and clinical characteristics of hydroxychloroquine retinopathy in the United Kingdom
Eye (2024)
-
Factors associated with early hydroxychloroquine-induced retinal toxicity in patients with systemic lupus erythematosus
Graefe's Archive for Clinical and Experimental Ophthalmology (2024)
-
A nationwide survey of hydroxychloroquine retinopathy presenting to the hospital eye service in the United Kingdom
Eye (2023)
-
Outcomes of screening for hydroxychloroquine retinopathy at the Manchester Royal Eye Hospital: 2 years’ audit
Eye (2023)
-
Hydroxychloroquine in nephrology: current status and future directions
Journal of Nephrology (2023)
